Business ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials GLP-1 Drugs Weight Loss Drugs Acquisitions Obesity Drugs Oncology Eli Lilly Weight Loss Medications Novo Nordisk Weight Management

Hims & Hers Shares Ease After Rally Fueled by Novo Nordisk Deal and Analyst Upgrades

The company is prioritizing Novo’s FDA-approved GLP-1 drugs to reduce regulatory risk.

Eli Lilly to Invest $3 Billion in China to Build Orforglipron Manufacturing

GSK to Acquire 35Pharma for $950 Million to Add Pulmonary Hypertension Candidate HS235

Vistagen Investors Face March 16 Lead‑Plaintiff Deadline as Law Firms Seek Clients

Analysts Reinforce Eli Lilly’s Bull Case on Strong 2026 Guide, GLP-1 Momentum

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

Bristol Myers, Janux Strike Exclusive Deal on Tumor-Activated T-Cell Engager

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

TG Therapeutics Lifts 2026 Outlook After Strong Briumvi Year, Shares Jump

Eli Lilly Prepares €15 Billion Abivax Offer, Eyes Next Wave of Weight-Loss Drugs

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength